Literature DB >> 16279242

Recurrent erysipelas: risk factors.

Felix Pavlotsky1, Shalom Amrani, Henry Trau.   

Abstract

BACKGROUND: Several systemic and regional risk factors have been described for erysipelas. However, those predisposing for recurrent episodes are not well defined.
MATERIALS AND METHODS: We performed a retrospective analysis of 574 patients hospitalized in our institution during a 3 year period. The analysis included demographic, epidemiologic, and medical chart review data with special attention to background disorders. The patients with single and recurrent episodes of erysipelas were compared.
RESULTS: The recurrent cases occurred mainly in the lower limb with several risk factors that were statistically more common than in the single episode group including overweight, venous insufficiency, lymphedema, tinea pedis, and previous regional surgical intervention or trauma.
CONCLUSIONS: Patients with erysipelas, especially when it involves the lower limb, should be instructed to reduce weight, control venous insufficiency and/or lymphedema and to emphasize prevention and treatment of tinea pedis. The role of prophylactic antibiotics requires further study.

Entities:  

Mesh:

Year:  2004        PMID: 16279242     DOI: 10.1046/j.1439-0353.2004.03028.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  13 in total

1.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

2.  Fungal infections of the feet in patients with erysipelas of the lower limb: is it a significant clinical problem?

Authors:  Katarzyna Korecka; Dominik Mikiel; Agnieszka Banaszak; Anna Neneman
Journal:  Infection       Date:  2021-02-03       Impact factor: 3.553

Review 3.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

4.  Genetic susceptibility to non-necrotizing erysipelas/cellulitis.

Authors:  Katariina Hannula-Jouppi; Satu Massinen; Tuula Siljander; Siru Mäkelä; Katja Kivinen; Rasko Leinonen; Hong Jiao; Päivi Aitos; Matti Karppelin; Jaana Vuopio; Jaana Syrjänen; Juha Kere
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

5.  Liposuction for Advanced Lymphedema: A Multidisciplinary Approach for Complete Reduction of Arm and Leg Swelling.

Authors:  John Boyages; Katrina Kastanias; Louise A Koelmeyer; Caleb J Winch; Thomas C Lam; Kerry A Sherman; David Alex Munnoch; Håkan Brorson; Quan D Ngo; Asha Heydon-White; John S Magnussen; Helen Mackie
Journal:  Ann Surg Oncol       Date:  2015-06-30       Impact factor: 5.344

6.  Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection.

Authors:  Yee Gyung Kwak; Seong Ho Choi; Tark Kim; Seong Yeon Park; Soo Hong Seo; Min Bom Kim; Sang Ho Choi
Journal:  Infect Chemother       Date:  2017-12

7.  Clinical Presentation and Laboratory Characteristics in Acute and Recurrent Erysipelas.

Authors:  Vesna Brishkoska-Boshkovski; Irena Dimitrovska; Irena Kondova-Topuzovska
Journal:  Open Access Maced J Med Sci       Date:  2019-03-14

8.  Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?

Authors:  Elham Ahmed Hassan; Abeer Sharaf El-Din Abdel Rehim; Mohamed Omar Abdel-Malek; Asmaa Omar Ahmed; Nourhan Mahmoud Abbas
Journal:  Clin Mol Hepatol       Date:  2019-06-10

9.  Impact of Compression Therapy on Cellulitis (ICTOC) in adults with chronic oedema: a randomised controlled trial protocol.

Authors:  Elizabeth Webb; Teresa Neeman; Jamie Gaida; Francis J Bowden; Virginia Mumford; Bernie Bissett
Journal:  BMJ Open       Date:  2019-08-15       Impact factor: 2.692

10.  Recurrent erysipelas--risk factors and clinical presentation.

Authors:  Malin Inghammar; Magnus Rasmussen; Adam Linder
Journal:  BMC Infect Dis       Date:  2014-05-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.